Nantes, June 10, 2025
XENOTHERA CONFIRMS PROGRESS IN THE TREATMENT OF PERIPHERAL T CELL
LYMPHOMA (PTCL) THROUGH ITS LIS22 ANTIBODY
Nantes-based biotech XENOTHERA confirms the value of its LIS22 antibody in the treatment of peripheral T-cell lymphomas (PTCL). The PALT1 clinical trial (NCT06495723) has just passed a new milestone at the trial’s scientific committee meeting, confirming continued recruitment. Clinical and biological safety, as well as injection tolerance, are encouraging. Preliminary efficacy data, yet to be confirmed, are very encouraging.
To date, 9 patients are participating in the trial. No DLT has been observed, so enrolment at the 6 mg/kg dose is continuing. PALT1 is a Phase I/II trial testing the safety and efficacy of LIS22 in patients with refractory relapsed PTCL. The trial is taking place in France and Italy, with Professor Gandhi Damaj at Caen University Hospital as principal investigator.
The results will be presented orally on Tuesday June 18 at 5:50 p.m. by Firas Bassissi, the biotech’s Scientific Director, at the World Congress on Lymphoma (18th International Conference on Malignant Lymphoma, Lugano, Switzerland, https://www.icml.ch/icml/congresses/18-icml/General-information.html#), during the “Experimental Medicines” session under the title “LIS22: An Effective Multimodal Polyclonal Antibody targeting T-Cell Malignancies”.
In addition, the PALT1 clinical trial is the subject of an abstract to be published in the proceedings of the same congress (abstract 847: “PALT trial: First in class glyco humanized polyclonal antibody directed against tumoral T cells, in patients with relapsed/refractory peripheral T cells lymphoma (PTCL)”).
“To be able to present LIS22 orally and to benefit from an abstract published in the proceedings of the Lugano World Congress is an immense source of pride, and confirms the interest of our treatment, as well as the recognition by the medical and scientific community of the quality and potential of our therapeutic antibody. I am of course delighted to be able to continue this trial, thanks to these results, which are both a validation of our approach and, above all, a source of hope for PTCL patients who have reached a therapeutic impasse. I would like to congratulate the XENOTHERA teams, and above all to thank the patients and medical teams who are working alongside us to analyze the therapeutic potential of LIS22,” says Odile Duvaux, President of the biotech company.
About XENOTHERA
Founded in 2014 by a team of renowned scientists and under the presidency of Odile Duvaux, Doctor of Medicine and Science, graduate of the École Normale Supérieure, XENOTHERA is a biotechnology company based in Nantes (France) that develops new therapeutic approaches in a wide range of fields, with a focus on oncology and immunology. The company develops treatments based on a unique multi-specific glyco-humanized antibody technology. Its technological platform is based on dual expertise in genetics and immunology. XENOTHERA is part of the scientific and medical environment of the Pays de la Loire region (France). Since its creation, the company has raised over 43 million euros, its main financiers being the Pays de la Loire Region, BPI France and the European fund EIC Fund, as well as private investors.
About LIS22
LIS22 is a GH-pAb from XENOTHERA’s therapeutic platform that targets several antigens present on tumor lymphocytes. LIS22 has been in clinical trials since 2024, and is funded by France 2030 (i-DEMO program). Preclinical studies have demonstrated that it recognizes most patients’ T lymphomas, is likely to destroy T lymphoma cells more effectively than CHOP, and has a significant anti-tumor effect in vivo (up to 90% reduction in tumor size). Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of non-Hodgkin’s lymphomas with a high medical need. PTCL are aggressive hematological tumors with a guarded prognosis. Patients are generally treated in the first instance with CHOP chemotherapy, whose efficacy is unfortunately limited, as is that of other treatments, whose response rate generally does not exceed 30%.
More information: www.xenothera.com
Follow XENOTHERA on social media: LinkedIn , X
Relations médias :
Akkanto
Carmen Borissova
+33(0)06 09 91 33 03
carmen.borissova@akkanto.fr / xenothera@akkanto.fr